Last reviewed · How we verify
Tegafur-Ugotex or Capecitabine
Tegafur-Uracil (Tegafur-Ugotex) is a combination prodrug that inhibits thymidylate synthase to block DNA synthesis in cancer cells.
Tegafur-Uracil (Tegafur-Ugotex) is a combination prodrug that inhibits thymidylate synthase to block DNA synthesis in cancer cells. Used for Colorectal cancer, Gastric cancer, Breast cancer.
At a glance
| Generic name | Tegafur-Ugotex or Capecitabine |
|---|---|
| Sponsor | Liaoning Cancer Hospital & Institute |
| Drug class | Antimetabolite; 5-fluorouracil prodrug |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Tegafur is a prodrug of 5-fluorouracil (5-FU) that is converted in the body to active 5-FU, which inhibits thymidylate synthase and disrupts nucleotide synthesis. Uracil is a competitive inhibitor of dihydropyrimidine dehydrogenase, the enzyme that degrades 5-FU, thereby prolonging 5-FU exposure and enhancing its cytotoxic effects. This combination allows for oral administration with improved bioavailability compared to intravenous 5-FU.
Approved indications
- Colorectal cancer
- Gastric cancer
- Breast cancer
Common side effects
- Hand-foot syndrome
- Diarrhea
- Nausea and vomiting
- Bone marrow suppression
- Stomatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegafur-Ugotex or Capecitabine CI brief — competitive landscape report
- Tegafur-Ugotex or Capecitabine updates RSS · CI watch RSS
- Liaoning Cancer Hospital & Institute portfolio CI